Irma Bagdoniene: Extreme Lipoprotein(a) Equals Secondary Prevention Risk in FH Patients
Irma Bagdoniene, Cardiologist and Lipidologist at Klinikum Lippe – University Hospital for Cardiology, Angiology, and Internal Intensive Care Medicine, posted on LinkedIn:
“This study highlights a important message: patients with extreme elevations of Lp(a) already carry a cardiovascular risk equivalent to secondary prevention — even in the primary prevention setting.
Implications for clinical practice:
- LDL-C targets of ≤70 mg/dL, ideally ≤55 mg/dL, are fully justified.
- Achieving these levels often requires combination therapy, including PCSK9 inhibitors.
- These high-risk patients deserve early, intensive lipid management—not only after their first event.
A strong reminder: FH AND extreme Lp(a) is a double-hit dyslipidemia that demands aggressive and early prevention strategies.”
Title: Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia
Authors: Martine Paquette, MSca, Bertrand Cariou, MDb, Simon-Pierre Guay, MDa,c,d, Antonio Gallo, MDe, Liam R. Brunham, MDf, Sophie Béliard, MDg, Alexis Baass, MD
Read full article here.
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology